Ad Hoc News

Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics

Ad hoc announcement pursuant to Art. 53 LR   GENEVA (Dec. 15, 2025) – MindMaze Therapeutics Holding SA (SIX: MMT...

Ad Hoc News

Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination

Ad hoc announcement pursuant to Art. 53 LR   GENEVA (Nov. 25, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, ...

Ad hoc news

Relief Therapeutics Shareholders Approve Business Combination with NeuroX

Ad hoc announcement pursuant to Art. 53 LR   Relief Therapeutics, a biopharmaceutical company committed to deliv...

Ad hoc news

Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032

Ad hoc announcement pursuant to Art. 53 LR   Relief Therapeutics, a biopharmaceutical company committed to deliv...

Ad hoc news

Relief Therapeutics Convenes Extraordinary General Meeting

Ad hoc announcement pursuant to Art. 53 LR   Relief Therapeutics, a biopharmaceutical company committed to deliv...

Ad hoc news

Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination

Ad hoc announcement pursuant to Art. 53 LR   Relief Therapeutics, a biopharmaceutical company committed to deliv...

Ad hoc news

Relief Therapeutics Publishes 2025 Half-Year Report

Ad hoc announcement pursuant to Art. 53 LR   Relief Therapeutics, a biopharmaceutical company committed to deliv...

Relief

Relief Therapeutics Advances Publication of 2025 Half-Year Report

GENEVA (Aug. 11, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a b...